November 2024
Novartis Announces 139 Job Cuts in New Jersey Amid Commercial Refocus
Novartis, job cuts, New Jersey, commercial refocus, restructuring
PTC Therapeutics Discontinues Utreloxastat Program Following Phase 2 ALS Trial Failure
PTC Therapeutics, Utreloxastat, ALS, Phase 2 Trial, CardinALS Study, Amyotrophic Lateral Sclerosis
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology
CDC Faces Uncertainty Amid Leadership Change and Funding Threats
CDC, leadership change, funding threats, public health, emerging health threats, Dave Weldon, Dr. Mandy Cohen
Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy
Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing
Acadia Pharmaceuticals Secures Exclusive License for SAN711, a Novel Essential Tremor Treatment
Acadia Pharmaceuticals, SAN711, Essential Tremor, Licensing Agreement, Saniona, GABAA-α3 Positive Allosteric Modulator
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring
Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).